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Fingolimod, also known as FTY720, is an analogue of the sphingolipid sphingosine, which has been 
proved to be neuroprotective in rodent models of Alzheimer’s disease (AD). Several cellular and 
molecular targets underlying the neuroprotective effects of FTY720 have been recently identified. 
However, whether the drug directly protects neurons from toxicity of amyloid-beta (Aβ) still remains 
poorly defined. Using a combination of biochemical assays, live imaging and electrophysiology we 
demonstrate that FTY720 induces a rapid increase in GLUN2A-containing neuroprotective NMDARs 
on the surface of dendritic spines in cultured hippocampal neurons. In addition, the drug mobilizes 
extrasynaptic GLUN2B-containing NMDARs, which are coupled to cell death, to the synapses. Altered 
ratio of synaptic/extrasynaptic NMDARs decreases calcium responsiveness of neurons to neurotoxic 
soluble Aβ 1–42 and renders neurons resistant to early alteration of calcium homeostasis. The fast 
defensive response of FTY720 occurs through a Sphingosine-1-phosphate receptor (S1P-R) -dependent 
mechanism, as it is lost in the presence of S1P-R1 and S1P-R3 antagonists. We propose that rapid 
synaptic relocation of NMDARs might have direct impact on amelioration of cognitive performance in 
transgenic APPswe/PS1dE9 AD mice upon sub-chronic treatment with FTY720.
Aggregates of amyloid beta (Aβ ) in the brain parenchyma and deposits of hyperphosphorylated tau in neurons 
are hallmarks of Alzheimer’s disease(AD), the most common neurodegenerative disorder characterized by synap-
tic dysfunction, neuronal loss and cognitive impairment. Consolidated evidence indicates that soluble Aβ forms 
and tau species rather than insoluble aggregates are responsible for neuronal damage and cognitive decline1–5. 
While molecular mechanisms mediating neurotoxicity of soluble tau forms largely remain to be elucidated, glu-
tamate ionotropic NMDA receptors (NMDARs) have emerged as specific targets of soluble Aβ 1–42 (s-Aβ ) oli-
gomers. NMDARs are among surface molecules which mediate s-Aβ interaction with neurons and evidence has 
been recently provided for a causal role of s-Aβ binding to or near NMDARs and neuronal damage1,6–8.
NMDARs are distinguished by localization and subunit composition in two functional distinct pools, which 
differentially regulate neuronal activity and survival9. Synaptic GLUN2A-containing NMDARs are neuropro-
tective and involved in plasticity phenomena. Extrasynaptic GLUN2B-containing NMDARs are coupled to cell 
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death10,11 and implicated in neurodegenerative disorders12,13. S-Aβ has been extensively demonstrated to pref-
erentially activate extrasynaptic GLUN2B-containing receptors14–16, although it elicits inward currents in both 
GLUN2A- and GLUN2B-containing NMDARs, when heterologously expressed in Xenopus laevis oocytes7.
Fingolimod, also known as FTY720, is an oral immunosuppressant, successfully used to treat multiple sclerosis17,18. 
It is an analogue of the sphingolipid sphingosine, and upon phosphorylation by sphingosine kinase 2 acts as 
sphingosine-1-phosphate (S1P) agonist on all S1P receptors (S1P-Rs), except S1P-R219. The therapeutic action of 
FTY720 in multiple sclerosis is mainly mediated by S1P-R1, a receptor which become internalized upon binding 
of FTY720-P. Decrease in functional S1P-R1s prevents egress of autoagressive T cells from lymph nodes and auto-
immune brain reaction20–22. Besides this peripheral action, FTY720 readily penetrates the CNS of rodents23,24 and 
humans25 and exerts protective effects on brain cells, including oligodendrocytes26, astrocytes27, microglia28,29 and 
neuron30–32. How the drug acts on neurons is not yet well understood, although neurons express S1P-Rs23,31,33–35 
and thus may be a direct cellular target of FTY720.
Thanks to its broad positive action on brain cells, FTY720 is emerging as promising neuroprotective agent 
in a wide range of CNS diseases. It exerts therapeutic benefit in preclinical models of stroke36–38 trauma39, Rett 
Syndrome40, epilepsy41 and also AD31,42–44. In rodents models of AD, i.e. rats or mice injected with Aβ , FTY720 
ameliorates memory impairment43–45, while in vitro it protects neurons from s-Aβ toxicity31,32. Multiple mecha-
nisms have been implicated in the protective action of FTY720 in AD, including inhibition of Aβ production from 
neurons42, modulation of microglia activation and cytokine release30, regulation of the ceramide/S1P balance46 
and up regulation of neuronal brain-derived neurotrophic factor (BDNF)31,40,43 a key modulator of memory 
formation47. Intriguingly, upregulation of the growth factor may be independent of S1P-R activation, resulting 
from nuclear action of FTY720, which inhibits histone deacetylases and exerts epigenetic control on genes asso-
ciated to learning and memory24, similarly to S1P.
In this study we suggest a new mechanism underlying direct protective action of FTY720 on neurons. We 
propose that the drug acutely protects neurons from s-Aβ toxicity by enhancing the functionality of synaptic ver-
sus extrasynaptic NMDARs through a S1PR-dependent mechanism. By this pathway the drug may contribute to 
amelioration of cognitive impairment in transgenic APPswe/PS1dE9 AD mice upon subchronic administration.
Results
Subchronic treatment with FTY720 improves memory performance and reduces s-Aβ 
concentration in APPswe/PS1dE9 transgenic mice. Previous evidence indicates that FTY720 ame-
liorates impairment in spatial memory and associative learning in rat or mice injected with Aβ 43,44. To explore 
the therapeutic potential of FTY720 in a transgenic AD mouse model, FTY720 (1 mg/Kg) or plain water was 
administered by oral gavage to 12 months-old APPswe/PS1dE9 and their littermates for 6 weeks. APPswe/
PS1dE9 mice develop first Aβ plaques at 4 months of age and clear cognitive defects at 12 months48. These mice 
do not exhibit neuronal loss, but display clinically relevant AD-like symptoms such as gliosis and microglio-
sis and correlation of the s-Aβ levels with behavioural deficits49. Pre-drug and post-drug behavioural analysis 
was carried out to test learning ability and different forms of memory performance, i.e., reference, episodic and 
innate memory, using the passive avoidance50 the novel object recognition51 and the nest building tasks (Zhe 
et al., 2013), respectively (Supplementary Fig. 1A–E). As expected, 12 months-old male APPswe/PS1dE9 mice 
showed basally (one week before treatment) (Supplementary Fig. 1B) severe deficits in reference memory in the 
passive avoidance task, in terms of reduced latency to re-enter in the dark compartment, where mice receive 
a mild foot shock (Supplementary Fig. 1B). After 5 weeks treatment with plain water their performance was 
further worsened. Conversely, their cognitive performance was significantly preserved upon treatment with 
FTY720 (Supplementary Fig. 1B, left). The novel object recognition memory task showed similar findings, 
revealing a reduced discrimination index during basal recordings and a further worsening in vehicle-treated 
APPswe/PS1dE9 mice. An improved recognition index was observed in FTY720-treated double transgenic mice 
(Supplementary Fig. 1C). Female APPswe/PS1dE9 mice were partially protected from memory impairment 
(Supplementary Fig. 1B). They were never impaired in the passive avoidance task, but became impaired in the 
novel object recognition task after 5 weeks of treatment with plain water, while maintained performance similar 
to wild type littermates upon FTY720 administration (Supplementary Fig. 1C). Measurements of basal locomotor 
activity excluded motor interference in the cognitive tasks. Indeed male mice, which were impaired in both cog-
nitive tasks, showed normal motor activity while female mice were slightly hyperactive (Supplementary Fig. 1D). 
Consistent with a therapeutic action of FTY720, in the nest building task, there was an improvement of nest build-
ing score in APPswe/PS1dE9 mice compared to corresponding vehicle-treated group (Supplementary Fig. 1E). In 
this task, no major difference in the behavior of male and female APPSwe/PS1 mice was observed.
We next examined the impact of subchronic FTY720 treatment on brain inflammation and Aβ content, 
the two clinically relevant AD-like symptoms of APPswe/PS1dE9 mice. A trend to decrease in the astrogliosis 
marker GFAP was observed by western blot analysis in APPswe/PS1dE9 mice administered with FTY720, while 
no changes in the microglial marker IBA-1 were detected in AD mice upon FTY720 treatment (not shown). 
Conversely, dot blot analysis of proteins extracted from the cortex of APPSwe/PS1 mice with anti-Aβ 6E10 
antibody showed a significant decrease in Aβ 1–42 levels in FTY720-treated mice (Supplementary Fig. 1F). 
In addition, Aβ 1–42 Elisa revealed a significant reduction in s-Aβ isolated in detergent-free buffer from 
the hippocampus of APPSwe/PS1 mice that received FTY720 as compared to mice treated with plain water 
(Supplementary Fig. 1G). The decrease was stronger in female than male transgenic mice (not shown).
FTY720 protects cultured neurons from acute s-Aβ toxicity. The decrease in Aβ content may 
account for amelioration of memory performance in the transgenic APPSwe/PS1 mouse. However, FTY720 may 
also render neurons less vulnerable to neurotoxic s-Aβ . We deeply investigated this hypothesis in vitro by explor-
ing how FTY720 impacts the viability of hippocampal neurons exposed to toxic s-Aβ .
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Our previous evidence indicates that cultured hippocampal neurons display abnormally high levels of cyto-
solic calcium as early as 1 h after exposure to s-Aβ 1–42 and eventually undergo cell death (within 24 h)32. We 
took advantage of this early sign of neurodegeneration to investigate the possibility of a precocious protective 
effect of FTY720. We recorded cytosolic calcium from 9 DIV neurons, loaded with the calcium dye Fura-2, 1 h 
after exposure to 1 μ M s-Aβ in the presence or in the absence of 200 nM FTY720. We found that FTY720 signif-
icantly protected neurons from early alterations of calcium homeostasis induced by s-Aβ (Fig. 1A), indicating 
Figure 1. FTY720 protects neurons from s-Aβ-induced calcium dysregulation by altering the binding of 
s-Aβ to neurons. Basal [Ca2+]i was measured in 9DIV neurons, loaded with the ratiometric calcium dye Fura-2 
and expressed as F340/380 fluorescence. (A) Representative pseudocolor images of basal [Ca2+]i in control 
neurons and in neurons exposed to s-Aβ alone or in combination with FTY720 for 1 h. Representative traces 
and quantification of basal [Ca2+]i are shown below. Values are normalized to control (the Kruskal–Wallis 
ANOVA, P = 0.002; Dunn’s test for comparison among groups, P = 0.05; N = 4). (B) Representative confocal 
images of 14DIV eGFP+ mouse neurons exposed to s-Aβ alone or in combination with FTY720, fixed and 
stained with the anti-Aβ antibody 6E10. Quantification of Aβ binding to neurons is shown below. The histogram 
shows density of Aβ puncta bound to neurons, (number of Aβ /eGFP colocalizing puncta normalized over eGFP 
area) (Mann-Whitney Rank Sum Test, P = 0.153; N = 3). (C) Representative confocal images of mouse neurons 
treated as in (B) and probed for 6E10 and the postsynaptic density marker shank-2. The panel below shows the 
fraction of Shank-2 puncta with bound Aβ (Mann-Whitney Rank Sum Test, P = 0.043; N = 3).
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a fast-acting protective action. Neuroprotection was completely lost in the presence of the S1P-R1 and S1P-R3 
selective antagonists W146 (10 μ M)52 and CAY1044 (10 μ M)53,54 (Fig. 1A), the S1P-Rs mainly expressed in hip-
pocampal neurons34,55.
FTY720 enhances binding of s-Aβ to synaptic sites. We then asked whether rapid neuroprotection 
by FTY720 may result from alteration in the binding of s-Aβ to neurons. 14–16 DIV eGFP positive neurons, 
established from a transgenic mouse line ubiquitously expressing eGFP under actin promoter, were incubated 
with s-Aβ (1 μ M) alone or in combination with 200 nM FTY720 for 1 h. Neurons were then extensively washed to 
remove unbound Aβ , fixed and stained with the anti-Aβ antibody 6E10. We did not observe significant changes 
of s-Aβ binding to eGFP positive neurites in FTY720-treated neurons (Fig. 1B). However, double staining of neu-
rons for 6E10 and the postsynaptic protein Shank-2 showed a significant increase in the fraction of postsynaptic 
sites with bound Aβ under drug treatment (Fig. 1C). Similar results were obtained in rat neurons (fraction of 
Aβ + Shank-2 puncta -normalized values-: control = 1.009 ± 0.06, FTY720 = 1.304 ± 0.07; N = 3, Mann-Whitney 
Rank Sum Test, P < 0.001; Data not shown). No changes in the density of Shank-2 positive puncta were observed 
upon 1 h exposure to s-Aβ (number of Shank-2 + puncta/ μ m: control = 0.81 ± 0.0350, s-Aβ = 0.83 ± 0.0279; 
number of dendrites analysed = 20; Data not shown).
FTY720 does not bind to Aβ species. Membrane lipids, including gangliosides and sphingolipids, are 
known to interact with both insoluble32,56 and soluble Aβ forms57 and to influence Aβ neurotoxicity. Thus, we 
explored whether FTY720, a sphingolipid analog, may interact with Aβ species and enhance their binding to 
synaptic neuronal receptors.
Direct interaction of FTY720 with Aβ forms was assessed by surface plasmon resonance (SPR)58. Briefly, Aβ 
monomers, oligomers, protofibrils and fibrils were immobilized on the sensor chip, and different concentrations 
of FTY720 (ranging from 125 to 1000 nM) were flowed over them. The resulting sensorgrams showed no relevant 
binding of FTY720 to Aβ species (Fig. 2A). We next investigated whether FTY720 might interfere with the forma-
tion of s-Aβ oligomeric species. In these experiments s-Aβ oligomers were recognized by their pseudo-irreversible 
binding to the anti-Aβ antibody 4G8 immobilized on the sensor chip59. Figure 2B shows that the presence of 
FTY720 (250–500 nM) did not affect the formation of Aβ oligomers from monomers. Finally, we monitored 
possible alteration in the kinetics of Aβ fibril formation using the thioflavin-T(ThT) assay. Aβ 1–42 (2 μ M) 
was incubated in the presence of 300–500 nM FTY720 and ThT at 28 °C. Time course analysis showed that in our 
conditions Aβ fibrillogenesis had a lag phase of 2 h, followed by very rapid growth, reaching a plateau after 5 h 
(Fig. 2C), and it was not affected by FTY720 (Fig. 2C).
Collectively these data rule out direct interaction between FTY720 and Aβ species, thus excluding that 
changes in Aβ conformation/aggregation may account for alteration in Aβ binding to synaptic sites.
FTY720 decreases functionality of extrasynaptic NMDARs while promotes activation of 
NMDARs at the synapse. Previous evidence indicates that s-Aβ forms activate acute calcium influx 
through NMDARs7,32,60, likely contributing to early dysregulation of calcium homeostasis (Fig. 1A). We thus 
investigated whether FTY720 may alter neuronal calcium responsiveness to acute challenge with s-Aβ or NMDA. 
We analysed calcium transients evoked by bath application of 4 μ M s-Aβ (in Mg2+ free solution, 1 μ M TTX and 
20 μ M CNQX to block AMPA/kainate receptors) in 12–15 DIV neurons, pre-incubated with FTY720 (200 nM) 
or vehicle for 1 h, during fura-2 loading. A significant reduction of calcium responses to s-Aβ was observed in 
FTY720-treated cultures (Fig. 3A–C). A similar decrease in calcium responses to 50 μ M NMDA (in Mg2+ free 
solution, 1 μ M TTX and 20 μ M CNQX) was observed in neurons pre-treated with FTY720 for 1 h (Fig. 3D,E), 
but not upon shorter drug treatment (Fig. 3F). The modulation of NMDA-mediated calcium responses was com-
pletely prevented in the presence of the S1P-R1 and S1P-R3 selective antagonists W146 and CAY1044, indicating 
a S1P-R-dependent action of the drug. No change of peak calcium responses to 50 μ M AMPA was observed in 
FTY720-treated neurons, suggesting specific modulation of NMDARs (AMPAR-mediated peak calcium tran-
sients expressed as DF340/380 -normalized values-: control = 1 ± 0.04, FTY720 = 1.056 ± 0.034, S1P-R1,3 antag-
onists = 1.05 ± 0.04; N = 3; One way Anova analysis of variance P = 0.398; Data not shown).
We next assessed the action of FTY720 on synaptic versus extrasynaptic NMDARs by employing a protocol 
to activate synaptic NMDARs and then isolate extrasynaptic NMDARs using the irreversible (in our experi-
mental time-frame) NMDAR channel blocker MK801 (adapted from ref. 61). Briefly, neurons were exposed to 
50 μ M bicuculline in low Mg2+, 1 mM AP4, 20 μ M CNQX and 30 μ M D-serine, a selective co-agonist of synap-
tic NMDARs9, to enhance spontaneous synaptic transmission and opening of synaptic NMDARs, followed by 
MK801 application (10 μ M), to block synaptic NMDARs. The extrasynaptic pools of NMDARs was then activated 
with 50 μ M NMDA in Mg2+ free solution, 1 μ M TTX and 20 μ M CNQX (Fig. 3G–I). Lower calcium responses 
mediated by extrasynaptic NMDARs were detected in neurons treated with FTY720 (Fig. 3G and I), in line 
with the general decrease in NMDAR-mediated calcium responses induced by the drug (Fig. 3E). Importantly, 
FTY720 sensitivity of extrasynaptic responses was greater than the sensitivity of calcium rises mediated by total 
NMDARs (Fig. 3I versus E; Mann-Whitney Rank Sum Test P = 0.003), suggesting that the drug may inhibit 
mostly extrasynaptic NMDARs. Accordingly, analysis of peak calcium responses mediated by synaptic NMDARs 
upon bicuculline application showed no decrease in calcium influx under treatment with FTY720 (Fig. 3G,H). 
Calcium responses mediated by synaptic NMDARs were actually larger in the presence of the drug, suggesting an 
increase in synaptic NMDAR function (Fig. 3H).
FTY720 decreases surface GLUN2B at extrasynaptic sites while increases surface GLUN2A and 
GLUN2B at synapses. To probe the molecular mechanisms underlying changes of functional NMDARs 
at extrasynaptic and synaptic sites we first investigated the effect of FTY720 on the expression and synaptic 
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localization of GluN2A and GluN2B subunits. Hippocampal neurons were incubated in the absence or presence 
of FTY720 (200 nM, 1 h), and then GluN2A and GluN2B synaptic levels were analyzed. The Triton-Insoluble 
Fraction(TIF), which is enriched in PSD proteins62, was obtained from control and FTY720-treated neurons, and 
protein levels measured by Western blotting. The analysis revealed no changes in the expression of either subunits 
in the total homogenate (Fig. 4A,B). FTY720 treatment significantly increased GluN2B synaptic levels without 
affecting GluN2A immunostaining in the TIF. We measured the GluN2B levels in the triton-soluble extrasynaptic 
membrane fractions (TSF) and we detected a decrease, albeit not significant, in such fraction, suggesting a mobi-
lization of GluN2B from the extrasynaptic to the synaptic sites. No detectable levels of GluN2A were observed in 
triton-soluble extrasynaptic membrane fractions (not shown), consistent with a dominant synaptic localization 
of the subunit, which remained stable in the synapse upon FTY720 exposure (Fig. 4A).
To further characterize changes in NMDARs distribution, we stained FTY720-treated and control hippocam-
pal cultures with antibodies directed against extracellular epitopes of GluN2A and GluN2B. The mean intensity 
of GluN2A puncta increased significantly in FTY720-treated neurons, indicating that FTY720 promotes GluN2A 
membrane insertion (Fig. 4C, left). An increase in the density of surface GluN2A puncta was also evident, but 
the change was not statistically significant (Fig. 4C, right). By contrast, the density of surface GLUN2B puncta 
(Fig. 4D right panel) decreased significantly in FTY720-treated cultures. Of note, mean intensity of GLUN2B 
puncta persisting at the neuron surface after drug treatment was unaffected (Fig. 4D right panel), suggesting that 
FTY720 may cause internalization of a subset of GLUN2B-containing NMDARs.
Selective loss of surface GLUN2B-containing NMDARs at extrasynaptic sites may account for reduced Ca2+ 
influx through extrasynaptic NMDARs. We indirectly tested this hypothesis by quantifying synaptic GLUN2B 
puncta, co-localizing with the presynaptic marker bassoon. No decrease in the fraction of synapses express-
ing surface GLUN2B was observed upon FTY720 treatment (Fig. 4F left panel), suggesting that loss of surface 
Figure 2. FTY720 does not interact with Aβ species and does not interfere with formation of Aβ oligomers 
or fibrillogenesis. (A) Synthetic Aβ 1–42 (100 μ M) was incubated in quiescent conditions for different time points 
in order to prepare the different Aβ species. We used freshly prepared solutions to have Aβ 42 monomers only; 5 h 
and 24 h incubation at 25 °C for maximal oligomers and protofibrils enrichment, respectively; fibrils were prepared 
by 24 h incubation at 37 °C at pH 2.0. These species were immobilized on the sensor chip coated whereas FTY720 
(concentrations indicated) was flowed from time = 0 to time = 300 sec. (B) Synthetic Aβ1–42 (100 μ M) was 
incubated at 25 °C in the absence or presence of different concentrations of FTY720. After 5 h samples were diluted 
100 fold in PBST and injected over immobilized 4G8 for 2 min, followed by 10 min of dissociation. The bars 
shows the SPR binding signal measured at the end of the dissociation period, which is indicative of the amount of 
captured Aβ oligomers. (C) Synthetic Aβ 1–42 (2 μ M) was incubated with ThT (10 μM) with or without FTY720, at 
two different dilutions. ThT fluorescence was continuously monitored for 13 h.
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GLUN2B receptors selectively occurs at extrasynaptic sites. Interestingly, mean intensity of GLUN2B synaptic 
clusters was significantly higher in FTY720-treated neurons (Fig. 4F right panel) as compared to control neu-
rons, suggesting possible mobilization of GLUN2B-containing NMDARs towards the synaptic membrane and 
strengthening the data obtained by biochemical fractionation (Fig. 4A). In line with enhanced synaptic GluN2B 
staining, we observed a significant shift of GLUN2B from extrasynaptic to synaptic sites in FTY720-treated neu-
rons (Fig. 4B). Thus, despite a global reduction of surface GluN2B, GluN2B expression increases on the synaptic 
membrane in neurons treated with FTY720.
Parallel analysis of surface GluN2A subunits at bassoon-positive synaptic sites showed an increased fraction of 
synapses expressing GluN2A subunits at the membrane (Fig. 4E left) and increased intensity of synaptic surface 
GluN2A fluorescence in FTY720-treated neurons (Fig. 4E right), indicating that FTY720 fosters GluN2A inser-
tion in the synaptic membrane.
FTY720 induces insertion into the synaptic membrane of new GLUN2A and mobilizes GLUN2B 
towards the synapse. We then monitored surface dynamics of GLUN2A and GLUN2B at postsynaptic 
spines upon FTY720 application by imaging 14 DIV neurons transfected with subunits tagged on the N ter-
minus with a pH-sensitive form of GFP (SEP-GLUN2A; SEP-GLUN2B)63. SEP-tagged subunits are mostly 
non-fluorescent when trapped intracellularly and display fluorescence when on the cell surface. To demarcate 
Figure 3. FTY720 increases the ratio between synaptic and extrasynaptic calcium-permeable NMDA 
receptors. (A) Representative pseudocolor images of Fura-2 loaded neurons (9DIV) maintained in control 
conditions or pre-treated with FTY720(200 nM, 1 h) before stimulation with s-Aβ (4 μ M) in Mg2+ -free medium 
and at peak [Ca2+]I responses. (B) Representative temporal plots of [Ca2+]I changes, expressed as F340/380, in 
control neurons and neurons exposed to FTY720 upon application of 4 μ M s-Aβ . Corresponding quantification 
of s-Aβ -induced [Ca2+]I responses is shown in (C) (Student’s t-test, P ≤ 0.001). (D) Representative temporal 
plots of [Ca2+]I changes in control neurons and neurons exposed to FTY720 upon bath application of 50 μ M 
NMDA. (E) Quantitative analysis of peak [Ca2+]I responses evoked by NMDA in control neurons, and neurons 
pre-incubated with FTY720 in the presence or not of S1P-R1 and S1P-R3 antagonists (Kruskal–Wallis ANOVA, 
P < 0.001; Dunn’s test for comparison among groups, P < 0.05). (F) Time course analysis of FTY720 action 
on calcium influx through NMDARs. (G) Representative time plot analysis of [Ca2+]I responses mediated by 
synaptic and extrasynaptic NMDARs, after MK801 block, in control neurons and neurons pre-incubated with 
FTY720 for 1 h. Corresponding quantification of synaptic and extrasynaptic [Ca2+]I responses are shown in 
(H) (Mann-Whitney Rank Sum Test, P < 0.001) and (I) (Kruskal–Wallis ANOVA, P < 0.001; Dunn’s test for 
comparison among groups, P < 0.05).
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spine morphology, neurons were co-transfected with td-Tomato. To determine whether FTY720 induces exocy-
tosis of GLUN2A/GLUN2B on the surface of spines we measured SEP fluorescence (mean fluorescence intensity) 
in circular region of interest (ROIs) manually positioned within the spines before and up to 1 h after drug appli-
cation. We observed a significant increase in SEP-GLUN2A signal in FTY720-treated spines compared to control 
spines at 50 and 60 min of recording (Fig. 4G and H). Similarly, after 60 min of recording, SEP-GLUN2B signal was 
significantly higher in spines treated with the drug compared to control spines, which showed a general tendency 
to decrease over time (Fig. 4I and J). The increase in surface expression of GLUN2A and GLUN2B at postsynaptic 
spines was associated to a shift towards a more mature (mushroom) spine morphology (Supplementary Fig. 2).
FTY720 increases the amplitude of NMDAR-mEPSCs, without changing in the ratio of synaptic 
GLUN2A/GLUN2B subunit. We finally investigated how changes in synaptic NMDARs driven by FTY720 
impact miniature NMDAR-excitatory postsynaptic currents (NMDAR-mEPSCs) induced by synaptically released 
glutamate. We recorded NMDAR-mEPSCs from 14–16 DIV hippocampal neurons at − 60 mV pretreated or not 
Figure 4. FTY720 modulates GLUN2B localization in the postsynaptic fraction and increases surface 
GLUN2B and GLUN2A expression at synapses. (A,B) Western blotting of the homogenate (HOMO), 
postsynaptic triton insoluble fraction (TIF) and triton soluble fraction (TSF) obtained from control and 
FTY720-treated hippocampal neurons (DIV14). Tubulin is used as loading control, while PSD-95 as a marker  
of postsynaptic fraction. FTY720 leads to an increased GLUN2B localization in the TIF leaving the total  
amount of GLUN2B unaltered while doesn’t alter GLUN2A localization in TIF (Student’s t-test, P = 0.0275 
N = 4). (C) Confocal images of neurons live stained for GLUN2A, fixed and counterstained against β 3-tubulin. 
Relative quantification of density of GLUN2A puncta are shown on the left (Mann-Whitney Rank Sum Test, 
P = 0.070) and mean intensity of GLUN2A clusters on the right (Mann-Whitney Rank Sum Test, P = 0.001). 
(D) Images of neurons live stained for GLUN2B and quantification of GLUN2B puncta density (Mann-Whitney 
Rank Sum Test, P = 0.003) and mean intensity (Student’s t-test, P = 0.610). (E,F) Images of neurons live stained 
for GLUN2A (E) or GLUN2B (F), fixed and counterstained against the presynaptic marker bassoon. Right 
histograms show quantification of GLUN2A positive synapses (Mann-Whitney Rank Sum Test, P ≤ 0.001) 
and GLUN2A puncta mean intensity (Mann-Whitney Rank Sum Test, P = 0.005) (number of analyzed 
puncta: control = 1010, FTY720 = 720; number of analyzed fields: control = 35; FTY720 = 30) or GLUN2B 
positive synapses (Mann-Whitney Rank Sum Test, P = 0.005) and GLUN2B puncta mean intensity (number 
of analyzed puncta: control = 1250, FTY720 = 807; number of analyzed fields: control = 37; FTY720 = 32). 
(G) Representative images of spines co-transfected with SEP-GluN2A(green) and dTom (red) acquired at the 
indicated time point in control and FTY720-treated neurons. (H) XY graph representing the DMFI/MFI0 of 
SEP-GluN2A over time (number of analysed spines: control = 40, FTY720 = 47; Mann-Whitney Rank Sum Test, 
P = 0.037 at t50 and P = 0.009 at t60). (I) Images of spines co-transfected with SEP-GluN2B and dTom as in G. 
(J) XY graph representing the DMFI/MFI0 of SEP-GluN2B over time (number of analysed spines: control = 15, 
FTY720 = 22; Mann-Whitney Rank Sum Test, P = 0.030 at t60).
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with FTY720, in the presence of TTX, bicuculline, strychnine (1 μ M), D-serine or glycine (10 μ M) and CNQX 
to block detection of fast AMPAR-mediated mEPSCs component, and in Mg2+ -free medium to allow record-
ing of the slow NMDAR component. We observed a significant increase in the amplitude of NMDAR-mEPSCs 
in FTY720-treated neurons as compared controls (Fig. 5A,B). The increase in NMDAR-mEPSC amplitude was 
not associated with frequency changes (Fig. 5C), consistent with a postsynaptic action of FTY720. Analysis of 
NMDAR-mEPSC sensitivity to the GLUN2B-selective antagonist ifenprodil (5 μ M) showed a similar block of 
NMDAR-mEPSCs amplitude in control and FTY720-treated neurons (Fig. 5D–F). This is consistent with an 
increased content of functional GLUN2B- and GLUN2A-containing NMDARs and no alteration in the ratio of 
synaptic GLUN2A/GLUN2B subunit.
Collectively these data show that FTY720 favours functionality of synaptic GluN2A- and GLUN2B-containing 
NMDARs.
Discussion
Our study strongly suggests a mechanistic link between neuroprotective effects of Fingolimod against 
Aβ –induced neurodegeneration and rapid relocation of functional NMDARs in cultured hippocampal neurons. 
Precisely, we show that the activation of S1P-R1 and S1P-R3 by Fingolimod drives quite rapid internalization 
of GLUN2B subunit at extrasynaptic regions and GLUN2B mobilization to the synapse, within a time scale of 
1 h, as revealed by Western blotting in the synaptic and extrasynaptic membrane fractions and imaging studies 
in hippocampal cultures. Augmented GLUN2B at the synapse is accompanied by increased surface GLUN2B 
expression, as indicated by quantitative immunofluorescence analysis and live imaging with SEP-GLUN2B. Rapid 
mobilization of GLUN2B from extrasynaptic regions is consistent with the well-known mobility of the subunit, 
that is dynamically regulated by neuronal activity64 and by several secreted molecules, such as neurotrophins65. 
Overall reduction of surface GLUN2B induced by FTY720 suggests that increased GLUN2B expression on the 
synaptic membrane results from lateral movement of extrasynaptic GLUN2B clusters, persisting on the cell sur-
face after treatment with the drug. However, we cannot exclude that new GLUN2B subunits could be inserted 
Figure 5. FTY720 increases the amplitude of NMDAR-mediated mEPSCs. (A) Mean NMDAR-mediated 
mEPSCs from control and FTY720-treated neurons (left) and corresponding representative traces (right).  
(B) Summary histogram showing the mean amplitudes of NMDAR-mediated mEPSCs from control and 
FTY720-treated neurons (number of cells: ctr = 35, FTY720 = 26; Student’s t-test, P = 0.002) (B-left); 
corresponding cumulative distributions of peak amplitudes from single representative cells (Kolmogorov-
Smirnov test, P ≤ 0.001) (B-right). (C) Summary histogram showing mean frequencies of neurons in B-left 
(Mann-Whitney Rank Sum test P = 0.507). (D,E) Summary histograms and line series plots showing the block 
of ifenprodil on mEPSC amplitude in control (D) and FTY720-treated neurons (E) (number of cells: ctr = 14, 
FTY720 = 9; ctr basal vs ifenprodil: paired t-test, P = < 0.001; FTY basal vs ifenprodil: paired t-test, P = 0.021) 
(D,E-left) and corresponding peak amplitude cumulative distributions from single representative cells (D,E-
right) (ctr basal vs ifenprodil: Kolmogorov-Smirnov test, P ≤ 0.001; FTY basal vs ifenprodil: Kolmogorov-
Smirnov test, P ≤ 0.001). (F) Residual NMDA mEPSC amplitude after Ifenprodil block (% residual amplitude 
ctr vs FTY: student t-test, P = 0.422).
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at synaptic sites following endocytosis from extrasynaptic regions upon drug treatment. Analysis of GLUN2B 
phosphorylation at residues controlling stabilization and anchoring of GLUN2B to neuron surface, such as 
Tyr147211,66–68 will provide further insights into the molecular mechanism underling GLUN2B relocation to the 
synapse.
Aside from GLUN2B, FTY720 changes the subcellular distribution of GLUN2A-containing NMDARs, by 
driving rapid insertion of new GLUN2A subunits into the synaptic membrane. Immunofluorescence analysis of 
surface GLUN2A and the use of SEP-GLUN2A indicate a clear upregulation of the subunit on neuronal mem-
brane, with no alteration in its location, which remains stable in the synaptic fractions.
As a result of GLUN2B mobilization to the synapse and GLUN2A insertion into the synaptic membrane, 
functional NMDARs raise at synaptic regions while decrease extrasynaptically. This is evidenced by enhanced 
NMDAR-mEPSC amplitude with no changes in the ratio of synaptic GLUN2A/GLUN2B subunit and by 
decreased calcium influx through extrasynaptic NMDARs in neurons treated with Fingolimod. Thus, FTY720 
emerges from the current study as key regulator of NMDAR trafficking, able to rapidly change the ratio of syn-
aptic versus extrasynaptic functional NMDARs. This mechanism may be behind augmented s-Aβ binding to 
synapses in FTY720-treated neurons.
Long standing evidence indicates that differentially located NMDARs are coupled to different intracellular 
cascades, with synaptic NMDARs being coupled to pro-survival pathways, primarily through nuclear Ca2+ sign-
aling, while extracellular NMDARs -present on the cell body or the dendritic shaft- activating several pro-death 
cascades69. While unbalance between synaptic and extrasynaptic NMDAR activity has been indicated as a com-
mon feature of neurological disorders, enhancement of synaptic NMDARs and disruption of extrasynaptic 
NMDAR-dependent death pathways have been proposed as therapeutic strategy for brain diseases12. Here we 
strongly suggest that FTY720 renders neurons resistant to Aβ toxicity exactly through this mechanism, favouring 
synaptic versus extrasynaptic NMDAR function through S1P-R activation. Indeed, the increased ratio of synaptic/
extrasynaptic NMDARs driven by FTY720 negatively correlates with the amplitude of harmful calcium responses 
of neurons to s-Aβ . Furthermore, it negatively correlates with early alterations of basal calcium concentration, 
which are detectable in neurons 1 h after treatment with s-Aβ . Conversely, pharmacological block of S1P-R1 and 
S1P-R3, which prevents the loss of functional extrasynaptic NMDARs induced by Fingolimod (and by S1P), com-
pletely neutralizes the positive action of the drug on calcium homeostasis. Of note, calcium responses mediated 
by extrasynaptic NMDARs become even larger in the presence of S1P-R1 and S1P-R3 antagonists. This evidence 
suggests that endogenous S1P may tonically inhibit extrasynaptic NMDARs, thereby constitutively limiting glu-
tamate excitotoxicity. To our knowledge these data represent first evidence that pharmacological modulation of 
S1P-Rs differentially regulates synaptic and extrasynaptic NMDARs and offers a realistic approach to interfere 
with early events in the excitotoxic cascade in neurodegenerative diseases.
By identifying NMDARs as key downstream effectors of S1P-Rs, responsible for early FTY720 neuropro-
tection, our data support and complement recent studies showing that FTY720 makes neurons resistant to 
excitotoxic concentration of NMDA30,40,52 and attenuates s-Aβ toxicity31. According to these studies, prolonged 
treatment with FTY720 (for at least 24 h in vitro) enhances the expression of BDNF, a neurotrophin involved in 
synaptic plasticity, downstream of S1P-R activation and ERK1/2 signalling, and restores normal BDNF expression 
in a mouse model of Rett syndrome40 and in mice injected with neurotoxic Aβ 44. It should be stressed, however, 
that the very early protective action of FTY720 we uncovered in our study, is not consistent with timing of induc-
tion of BDNF transcript. Although applied in the non phosphorylated, inactive form, FTY720 relocates GLUN2B 
and changes the ratio of synaptic/extrasynaptic NMDARs in only 1 h in vitro. Within this time window, the drug 
also shifts Aβ binding to synaptic regions and significantly reduces damage to neurons when co-applied with toxic 
Aβ species. On the other hand, a rapid increase in BDNF protein translation has been recently described upon 
acute dose of the NMDAR antagonist ketamine70,71. Thus, we cannot exclude that de-repression of BDNF trans-
lation may occur and contribute to fast protective signaling downstream inhibition of extrasynaptic NMDARs 
upon FTY720 treatment. Further work needs to be done to explore possible changes of BDNF protein upon acute 
FTY720 treatment.
It has been recently shown that FTY720 is equally efficient as the NMDAR antagonist memantine, an approved 
drug to treat AD symptoms, in partly reversing changes of gene expression induced by Aβ injection in rodents44. 
By showing that FTY720 acts as functional antagonist of extrasynaptic GLUN2B-containing NMDARs, we here 
provide a possible mechanism underlying the positive action of the drug on the expression of genes altered by Aβ .
More importantly, synaptic relocation of GLUN2B-containing NMDARs mediated by FTY720 might have 
direct impact on synaptic plasticity and memory processes and underlie the increase in cognitive performance 
observed in AD mice after drug treatment (this study Supplementary Fig. 1; Asle-Rousta, 2013 #696}43,44. 
Consistent with this possibility recent works show that FTY720 significantly facilitates both LTP in hippocampal 
slices24 and that synaptic activation of GLUN2B-containing NMDARs is essential for the formation of LTP, the 
physiological mechanism behind memory72,73.
Thus, beyond a fast defensive response against s-Aβ excitoxicity, facilitation of synaptic versus extrasynaptic 
NMDAR function makes this drug, acting on multiple brain cell targets, a really promising neuroprotective agent, 
able to directly influence the key postsynaptic effectors of synaptic plasticity, i.e. NMDARs, in a S1P-Rs-dependent 
manner.
Materials and Methods
Animals. For behavioral analysis 12-month-old male and female APPswe/PS1dE9 transgenic mice and age-
matched littermates were used. All the experimental procedures followed the guidelines established by the Italian 
Council on Animal Care (L.D. no 26/2014) and were approved by the Milano University Bioethical Committee. 
All efforts were made to minimize the number of subjects used and their suffering. APPswe/PS1dE9 mice and 
their littermates were housed in independent cages, with free access to food and water at 22 °C and with a 12-h 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7:41734 | DOI: 10.1038/srep41734
alternating light/dark cycle. For behavioral profile animals were tested once for each test. All the tests were carried 
out between 8.00 and 14.00.
Motor function. Spontaneous motor activity was evaluated in an automated activity cage placed in a sound 
attenuating room as previously described74. Cumulative horizontal beam breaks were counted for 15 min.
Passive avoidance. The apparatus consisted of two compartments, one light and one dark, connected via 
a sliding door. In the acquisition trial, each mouse was placed in the light compartment and allowed to enter the 
dark compartment as previously described75. The time(in s) taken to do so was recorded. Once the mouse was 
in the dark compartment, the sliding door was closed and an unavoidable electric shock (1 mA for 1 s) delivered 
via the paws. The animal was then placed back in the home cage until the retention trial. The retention trial was 
carried out 24 h after the acquisition trial, by positioning the mouse in the light compartment and recording the 
time taken to enter the dark compartment (retention latency). An increased retention latency indicates that the 
animal has learned the association between the shock and the dark compartment. During the retention trial, a 
cut-off time of 180 s was used. An experimenter blind to the treatment group manually recorded the latency time.
Novel object recognition (NOR). The test was conducted over a two-day period in an open plastic arena 
(60 cm × 50 cm × 30 cm), as previously described74. Animals were habituated to the test arena for 10 min on the 
first day. After 1-day habituation, mice were subjected to familiarization (T1) and novel object recognition (T2). 
During the initial familiarization stage, two identical objects were placed in the center of the arena equidistant 
from the walls and from each other. Each mouse was placed in the center of the arena between the two objects 
for a maximum of 10 min or until it had completed 30 s of cumulative object exploration. Object recognition was 
scored when the animal was within 0.5 cm of an object with its nose toward the object. Exploration was not scored 
if a mouse reared above the object with its nose in the air or climbed on an object. Mice were returned to the home 
cage after familiarization and then tested again after a delay of 2 hours. A novel object (never seen before) took 
the place of one of the two familiars. An experimenter blind to the treatment group manually recorded the explo-
ration times to the objects for each animal. Performance was evaluated by discrimination index (N − F/N + F) 
where N = time spent exploring the new object during T2, F = time spent exploring the familiar object during T2.
Nest building. The nest building test was performed in the home cage led with 0.5 cm bedding according to 
ref. 76. Each cage was supplied with a “Nestlet”, a 5 cm square of pressed cotton batting, one hour before the dark 
phase. Results were assessed the next morning. The nests were assessed on a 5-point scale:
1. The Nestlet is largely untouched (> 90% intact).
2. The Nestlet is partially torn up (50–90% remaining intact).
3. The Nestlet is mostly shredded but often there is no identifiable nest site: < 50% of the Nestlet remains 
intact but < 90% is within a quarter of the cage floor area, i.e. the cotton is not gathered into a nest but 
spread around the cage. Note: the material may sometimes be in a broadly defined nest area but the critical 
definition is that 50–90% has been shredded.
4. An identifiable, but flat nest: > 90% of the Nestlet is torn up, the material is gathered into a nest within a 
quarter of the cage floor area, but the nest is flat, with walls higher than mouse body height (curled up on 
its side) on less than 50% of its circumference.
5. A (near) perfect nest: > 90% of the Nestlet is torn up, the nest is a crater, with walls higher than mouse body 
height on more than 50% of its circumference.
This procedure was repeated each day for 4 consequent days. An experimenter blind to the treatment group 
manually evaluated the nest building with an appropriate score.
Hippocampal neurons. Primary neuronal cultures were obtained from the hippocampi of 18-day-old fetal 
Sprague Dawley rats of either sex (Charles River Italia), or C57BL/6 GFP transgenic mice with the GFP gene 
controlled by the actin promoter77 (of either sex). Briefly, dissociated cells were plated onto poly-L-lysine (Sigma 
Aldrich, St. Louis, MO) treated coverslips and maintained in Neurobasal with 2% B27 supplement (Invitrogen, 
Carlsbad, CA), antibiotics, glutamine and glutamate. Neurons were used at 9–16 DIV.
Aβ 1–42 preparation. To prepare soluble Aβ 1–42, the peptide (Anaspec, Fremont, CA) was initially mon-
omerized by dissolving it in 100% hexafluoroisopropanol (Sigma, St. Louis, MO, USA) to obtain a 1 mM solu-
tion and then aliquoted in sterile microcentrifuge tubes. The hexafluoroisopropanol was removed under vacuum 
using a SpeedVac and the peptide film was stored (desiccated) at − 80 °C. Soluble Aβ was prepared as previously 
described78. Briefly, the peptide film was freshly resuspended in 100% DMSO to 5 mM, further diluted to 100 μ M 
in F-12 medium (Invitrogen, Paisley PA4 9RF, UK) and incubated for 24 h at 4 °C. Following incubation it was 
centrifuged at 14,000 g for 10 min at 4 °C and the soluble forms were collected in the supernatant.
For SPR and ThT studies depsi-Aβ 1–42 was synthesized in-house, as previously79. The depsi-peptide is 
much more soluble than the native one and has much less propensity to aggregate, preventing the spontaneous 
formation of seeds in solution. Aβ 1–42 was then obtained from the depsi-peptide by a “switching” procedure 
involving a change in pH80. The solution was diluted in 10 mM PBS, pH 7.4, to a final concentration of 100 μ M 
and incubated at 25 °C in quiescent conditions for different times. We used freshly prepared solutions (t = 0) to 
have Aβ monomers only, Aβ solutions incubated for 5 h (t = 5 h) for maximal Aβ oligomer enrichment, whereas 
incubation for 24 h allowed formation of protofibrils59. To prepare Aβ 1–42 fibrils, the switched peptide solution 
was diluted with water to 100 μ M, acidified to pH 2.0 with 1 M HCl, and left to incubate from 20 to 24 h at 37 °C.
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SPR studies. SPR studies were carried out with the ProteOn XPR36 Protein Interaction Array System 
(Bio-Rad Laboratories, Hercules, CA) based on SPR technology. Aβ 1–42 species were immobilized in 
parallel-flow channels of the same GLC sensor chip (Biorad) using amine-coupling chemistry, as previously 
described58. A reference surface was always prepared in parallel using the same immobilization procedure but 
without addition of the peptide. The potential interaction of FTY720 was then evaluated by injecting four differ-
ent concentrations of the compound (125–1000 nM), as well as the vehicle over the immobilized ligands or con-
trol surfaces, in parallel, at the same time. The signal in the surfaces immobilizing Aβ was corrected by subtracting 
the nonspecific response observed in the reference surface. In another set of SPR experiments, the anti-Aβ anti-
body 4G8 (Covance, Princeton, NJ, USA) was immobilized on GLC sensor chips (Bio-Rad) using amine-coupling 
chemistry, as previously described59. A reference surface, using the same immobilization procedure but without 
addition of the antibody, was always prepared in parallel. Oligomer-enriched Aβ 1–42 solutions (i.e. incubated 
for 5 h) diluted to a final Aβ 1–42 concentration of 1 μ M, were flowed over the chip surfaces for 2 min, followed 
by 10-min flow with running buffer (dissociation phase). According to our previous data, the SPR signal meas-
ured at the end of the session is only due to oligomers (Aβ monomers completely dissociate from 4G8 after 
10 min in running buffer, whereas most oligomers remain pseudo-irreversibly bound to the antibody ref. 59). 
In order to evaluate the effect of FTY720 on the oligomers formation, Aβ 1–42 solutions were incubated for 5 h 
in the absence or presence of FTY720 and then injected over immobilized 4G8. The running buffer, also used to 
dilute the samples, was 10 mM PBS containing 150 mM NaCl and 0.005% Tween 20 (PBST). All these assays were 
performed at 25 °C. The sensograms (time-course of the SPR signal in RU) were normalized to a baseline value 
of 0. The signal observed on the surfaces immobilizing antibodies was corrected by subtracting the nonspecific 
response observed on the reference surface.
ThT studies. A freshly prepared solution of Aβ 1–42 (2 μ M) was incubated with 10 μ M thioflavinT (ThT) with 
or without FTY720, and the ThT fluorescence was monitored for 13 h79. In‐situ ThT kinetic experiments were 
done on a plate reader (M200 Infinity, Tecan) using a 96‐well black plate with flat transparent bottom. The dye 
was excited at 440 nm and emission was taken at 495 nm.
Calcium Imaging. 9–14 DIV hippocampal neurons were loaded with 2 μ M Fura-2 pentacetoxy methylester 
for 40 min at 37 °C, washed and transferred to the recording chamber of an inverted microscope (Axiovert 100; 
Zeiss, Oberkochen, Germany) equipped with a calcium imaging unit Polychrome V (TILL Photonics, Germany) 
as described81. Images were collected with a CCD Imago-QE camera (TILL Photonics GmbH) and analyzed with 
TILLvisION 4.5.66 software. After excitation at 340 and 380 nm wavelengths, the emitted light was acquired at 
505 nm at 1 Hz. Calcium concentration was expressed as F340/F380 fluorescence ratio. The ratio values in selected 
region of interest corresponding to neuronal cell bodies were calculated from sequences of images to obtain tem-
poral analysis. Basal calcium concentration was recorded from at least 100 neurons/condition in each experiment.
Activation of synaptic/extrasynaptic NMDARs. Neurons were exposed to low Mg2+ KRH (125 mM NaCl, 
5 mM KCl, 1.2 mM KH2PO, 2 mM CaCl2, 0.6 mM MgSO4, 6 mM D-glucose, and 25 mM HEPES/NaOH, pH 7.4) 
containing 50 μ M bicuculline, 1 mM APV, 30 μ M D-serine and 20 μ M CNQX to activate synaptic NMDARs 
followed by 10 μ M MK801 for 3 min to block synaptic NMDARs. Then neurons were washed several times to 
remove unbound MK801, followed by incubation in Mg2+ free KRH containing CNQX and TTX and 50 μ M 
NMDA to selectively activate extrasynaptic NMDARs.
Surface staining for GLUN2A and GLUN2B. Quantification of total surface and synaptic signal. 
Living neurons were incubated for 10 min with rabbit antibodies directed against extracellular epitopes of 
GLUN2A (1:100, Invitrogen, CA, USA) or GLUN2B (1:100, Alomone Labs, Jerusalem, Israel), washed and fixed 
with 4% paraformaldehyde and 4% sucrose. The following antibodies were used to double stain the cultures: 
guinea pig anti-Bassoon (1:500, Synaptic System, Goettingen, Germany), mouse anti-beta III tubulin (1:500; 
Promega Corporation, Madison, WI, USA). Secondary antibodies were conjugated with Alexa-488, Alexa-
555, Alexa-633 (Alexa-Invitrogen, San Diego, CA). Images were acquired using a Leica SPE confocal micro-
scope equipped with an ACS APO × 63/1.30 oil objective (Leica Microsystems, Solms, Germany. Acquisition 
parameters (i.e., laser power, gain and offset) were kept constant among different experimental settings. Surface 
GLUN2A/GLUN2B staining was quantified as follows. Number of GLUN2A/GLUN2B puncta were measured 
using Image J 1.46r software in GLUN2A/GLUN2B fluorescence images after setting a fixed threshold using the 
‘analyze particle’ function. Number of GLUN2A/GLUN2B puncta in each field (devoid of neuronal cell bodies) 
were then normalized to β -tubulin area after setting a fixed threshold to obtain density of GLUN2A/GLUN2B 
puncta. All data are results of at least 3 independent experiments. GLUN2A/GLUN2B puncta colocalizing with 
bassoon were manually selected to measure mean intensity and size of single puncta. Approximately 75 spines per 
field were measured in at least ten fields per independent experiments.
Analysis of s-Aβ binding to neurons. s-Aβ was prepared as described above and incubated for 1 h with 
mouse neurons from C57BL/6J-GFP transgenic mice or wild type mouse/rat hippocampal neurons. Neurons 
were then fixed and stained with rabbit anti-Shank-2 (1:500, NeuroMab, Davis, CA). s-Aβ binding to eGFP pos-
itive neuritis was quantified as follows. Aβ and eGFP double-positive puncta (bound Aβ ) were revealed by gen-
erating a Aβ /eGFP double-positive image using the ‘and’ option of ‘image calculator’ function. A fixed threshold 
was then set in the double-positive image and number of double-positive puncta was quantified using the ‘analyze 
particle’ function. Total eGFP fluorescence area was directly measured in the green channel, after setting a fixed 
threshold. Finally, number of Aβ /eGFP colocalizing puncta was normalized to eGFP area in each field to obtain 
density of bound Aβ puncta. A similar procedure was used to quantify s-Aβ binding to postsynaptic spines. Aβ 
and Shank-2 double-positive puncta (synaptic Aβ ) were revealed by generating a Aβ /Shank-2 double-positive 
www.nature.com/scientificreports/
1 2Scientific RepoRts | 7:41734 | DOI: 10.1038/srep41734
image. A fixed threshold was then set in the double-positive image and number of Aβ -positive puncta was meas-
ured and normalized to total number of Shank-2 puncta to obtain the fraction of Aβ positive postsynaptic spines.
Live imaging with SEP constructs. Control and FTY720-treated neurons were maintained in neurobasal 
medium without phenol red, supplemented with B27 in the incubator chamber of an inverted LSM510 confo-
cal microscope (Zeiss, Jena, Germany). SEP-GluN2A/dTom or SEP-GluN2B/dTom images were acquired, every 
10 min for 1 h. Mean fluorescence intensity (MFI) was measured using ImageJ software at ROIs selected within 
only those spines that were stable over 1 h, after setting a fixed threshold. Δ MFI/MFI0, was then calculated and 
plotted.
Electrophysiological recordings. Whole-cell voltage clamp recordings were performed using a 
MultiClamp 700A amplifier (Axon Instruments) coupled to a pCLAMP 10 Software (Molecular Devices), and 
using an inverted Axiovert 200 microscope (Zeiss). NMDA-mEPSCs were recorded from 14–15 DIV hippocam-
pal neurons plated at a density of 1.7 × 105 neurons/coverslip at room temperature (20–25 °C). Holding poten-
tial was set at − 60 mV and a Cesium Gluconate (CsGluc) internal solution was used: 130 mM CsGluc, 8 mM 
CsCl, 2 mM NaCl, 10 mM HEPES, 4 mM EGTA, 4 mM MgATP, 0.3 mM Tris-GTP (pH 7.3, adjusted with CsOH). 
Mg2+ -free KRH was used as external solution and recordings were performed in the presence of 1 μ M tetrodo-
toxin, 20 μ M CNQX, 20 μ M bicuculline, all from Tocris (Bristol, UK), 1 μ M strychnine, 10 μ M D-serine or 10 μ M 
glycine, all from Sigma Aldrich (St. Louis, MO). Signals were sampled at 10 kHz and filtered to 2 kHz. Recording 
pipettes were fabricated from capillary glass using a two-stage puller (Narishige, Japan) to have a tip resistances of 
3–5 MΩ. Series resistance was monitored before and during experiments. In a set of experiments we applied 100 μ M 
APV to determine whether slow currents recorded were actually mediated by NMDAR. NMDA-mEPSC traces 
were analyzed with Clampfit Software using a threshold of 3 pA. FTY720 was administrated at 200 nM for 1 h.
TIF preparation. Triton insoluble fractions (TIFs) were isolated from DIV14 hippocampal neurons as pre-
viously described82. Cells were homogenized in ice-cold sucrose 0.32 M containing 1 mM Hepes, 1 mM MgCl2, 
1 mM EDTA, 1 mM NaHCO3, 0.1 mM PMSF, at pH 7.4 and centrifuged at 800 × g for 5 min. The resulting super-
natant (S1) was centrifuged at 13,000 × g for 15 min to obtain a crude membrane fraction (P2 fraction). The 
pellet was resuspended in buffer containing 75 mM KCl and 1% Triton X-100 and centrifuged at 100,000 × g for 
1 h at 4 °C. The supernatant was stored and referred as Triton soluble fraction (TSF). The final pellet (TIF) was 
homogenized in a glass-glass potter in 20 mM Hepes and stored at − 80 °C until processing. All purifications 
were performed in presence of a complete set of protease inhibitors (Complete, Roche) and of both Ser/Thr- and 
Tyr-phosphatase inhibitor cocktails (Sigma-Aldrich).
Reagents. FTY720 and CAY10444 were from Cayman Chemicals (Ann Arbor, MI) and W146 from Avanti 
Polar Lipids (Alabaster, Alabama). Tetrodotoxin, CNQX, bicuculline, APV, NMDA, AMPA were all from Tocris 
(Bristol, UK). Strychnine, D-serine, glycine, Fura-2/am, MK801, from Sigma Aldrich (St. Louis, MO).
Data analysis. All data are expressed as means ± SEM. Behavioral data were statistically analyzed and dis-
played by Prism 6 software (GraphPad, San Diego, CA). Two-way ANOVA for multiple comparisons, followed by 
Bonferroni’s test was used to evaluate the difference among groups for behavioural data. Kolmogorov-Smirnov 
test was used for comparing cumulative distributions in NMDA mEPSC amplitude analysis; the test was per-
formed using Origin8 software. All other data were first tested for normal distribution with SigmaStat 3.5 soft-
ware, and the appropriate statistical test was been used (see figure legends). The accepted level of significance 
was p ≤ 0.05, indicated by an asterisk; those at P was ≤ 0.01 are indicated by double asterisks, while the ones at 
P ≤ 0.001 are indicated by triple asterisk.
Sample size was chosen according to G*Power software. Not healthy neurons were excluded from the analysis, 
based on basal calcium levels, morphology and electrophysiological parameters (resting membrane potentials, 
series resistance, leak currents), which were monitored at the beginning and during recordings. We chose compa-
rable samples (neuronal coverslips from the same preparation, plated at the same cell density/mice) and utilized 
them randomly for controls and experimental treatments.
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